IL286818B1 - Mirikizumab for use in a method of treating crohns disease - Google Patents

Mirikizumab for use in a method of treating crohns disease

Info

Publication number
IL286818B1
IL286818B1 IL286818A IL28681821A IL286818B1 IL 286818 B1 IL286818 B1 IL 286818B1 IL 286818 A IL286818 A IL 286818A IL 28681821 A IL28681821 A IL 28681821A IL 286818 B1 IL286818 B1 IL 286818B1
Authority
IL
Israel
Prior art keywords
mirikizumab
administered
weeks
dose
treatment
Prior art date
Application number
IL286818A
Other languages
English (en)
Hebrew (he)
Other versions
IL286818A (en
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL286818A publication Critical patent/IL286818A/en
Publication of IL286818B1 publication Critical patent/IL286818B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
IL286818A 2019-04-22 2021-09-29 Mirikizumab for use in a method of treating crohns disease IL286818B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962836910P 2019-04-22 2019-04-22
PCT/US2020/028273 WO2020219314A1 (en) 2019-04-22 2020-04-15 Mirikizumab for use in a method of treating crohn's disease

Publications (2)

Publication Number Publication Date
IL286818A IL286818A (en) 2021-10-31
IL286818B1 true IL286818B1 (en) 2025-11-01

Family

ID=70554215

Family Applications (2)

Application Number Title Priority Date Filing Date
IL286818A IL286818B1 (en) 2019-04-22 2021-09-29 Mirikizumab for use in a method of treating crohns disease
IL324048A IL324048A (en) 2019-04-22 2025-10-19 Mirikizumab for use in the treatment of Crohn's disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL324048A IL324048A (en) 2019-04-22 2025-10-19 Mirikizumab for use in the treatment of Crohn's disease

Country Status (17)

Country Link
US (1) US20220040299A1 (enExample)
EP (1) EP3958897A1 (enExample)
JP (3) JP7297930B2 (enExample)
KR (2) KR20250153865A (enExample)
CN (2) CN119700968A (enExample)
AU (2) AU2020263238C1 (enExample)
BR (1) BR112021018930A2 (enExample)
CA (1) CA3134587A1 (enExample)
EA (1) EA202192532A1 (enExample)
IL (2) IL286818B1 (enExample)
MA (1) MA55756A (enExample)
MX (1) MX2021012848A (enExample)
SG (1) SG11202110619XA (enExample)
TW (2) TWI850365B (enExample)
UA (1) UA128657C2 (enExample)
WO (1) WO2020219314A1 (enExample)
ZA (1) ZA202108094B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI850365B (zh) * 2019-04-22 2024-08-01 美商美國禮來大藥廠 治療克隆氏症(crohn's disease)的方法
KR20220066831A (ko) 2020-11-16 2022-05-24 엔브이에이치코리아(주) 습기경화형 접착제를 이용한 헤드라이닝 제조방법 및 이에 의해 제조되는 헤드라이닝

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017048901A1 (en) * 2015-09-18 2017-03-23 Boehringer Ingelheim International Gmbh Methods of treating inflammatory diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20140049B1 (ar) 2013-03-08 2021-08-17 Lilly Co Eli أجسام مضادة ترتبط بـ il-23
EP3693007A1 (en) 2013-03-15 2020-08-12 Amgen, Inc Methods for treating crohn's disease using an anti-il23 antibody
AU2017312049A1 (en) * 2016-08-19 2019-02-21 Janssen Biotech, Inc. Methods of treating Crohn's Disease with an anti-NKG2D antibody
KR20200037258A (ko) * 2017-07-10 2020-04-08 람밤 메드-테크 엘티디. 생물학적 약물로 치료받은 피험자에서 중화 항체 수준 평가용 분석법 및 맞춤 의료에서 이의 사용
TWI850365B (zh) * 2019-04-22 2024-08-01 美商美國禮來大藥廠 治療克隆氏症(crohn's disease)的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017048901A1 (en) * 2015-09-18 2017-03-23 Boehringer Ingelheim International Gmbh Methods of treating inflammatory diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHRISTOPHER MA ET AL,, INVESTIGATIONAL DRUGS IN PHASE I AND PHASE II CLINICAL TRIALS TARGETING INTERLEUKIN 23 (IL23) FOR THE TREATMENT OF CROHN'S DISEASE, 3 August 2018 (2018-08-03) *

Also Published As

Publication number Publication date
CN119700968A (zh) 2025-03-28
JP2022530397A (ja) 2022-06-29
JP7761614B2 (ja) 2025-10-28
AU2020263238C1 (en) 2024-02-22
KR20210142704A (ko) 2021-11-25
AU2023265759A1 (en) 2023-12-07
TW202103734A (zh) 2021-02-01
US20220040299A1 (en) 2022-02-10
BR112021018930A2 (pt) 2022-01-18
CA3134587A1 (en) 2020-10-29
UA128657C2 (uk) 2024-09-18
IL324048A (en) 2025-12-01
CN113677366A (zh) 2021-11-19
EP3958897A1 (en) 2022-03-02
WO2020219314A1 (en) 2020-10-29
JP7297930B2 (ja) 2023-06-26
EA202192532A1 (ru) 2022-01-21
AU2020263238A1 (en) 2021-11-04
ZA202108094B (en) 2025-05-28
NZ781127A (en) 2025-06-27
IL286818A (en) 2021-10-31
AU2020263238B2 (en) 2023-08-17
SG11202110619XA (en) 2021-11-29
TWI850365B (zh) 2024-08-01
JP2023116680A (ja) 2023-08-22
JP2025148449A (ja) 2025-10-07
MX2021012848A (es) 2021-12-10
KR102869852B1 (ko) 2025-10-14
KR20250153865A (ko) 2025-10-27
TW202515610A (zh) 2025-04-16
MA55756A (fr) 2022-03-02

Similar Documents

Publication Publication Date Title
JP7571225B2 (ja) 潰瘍性大腸炎を治療する方法
JP2025148449A (ja) クローン病を治療する方法に使用するためのミリキズマブ
EA045979B1 (ru) Мирикизумаб для применения в способе лечения болезни крона
HK40101440A (en) Mirikizumab in the treatment of ulcerative colitis
HK40036550A (en) Mirikizumab in the treatment of ulcerative colitis
HK40036550B (en) Mirikizumab in the treatment of ulcerative colitis
EA049081B1 (ru) Способы лечения язвенного колита